Enigma Biomedical - USA Announces Appointment of Hartmuth Kolb, PhD as Chief Scientific Officer
Retrieved on:
Tuesday, February 13, 2024
Research, General Health, Radiology, Pharmaceutical, Biometrics, Medical Devices, Health Technology, Science, Biotechnology, Neurology, Other Science, Health, Organic chemistry, FNIH, Neuroscience, Doctor of Philosophy, Nobel Prize in Chemistry, NIH, Professor, SVP, Johnson & Johnson, Hartmuth C. Kolb, Neurodegenerative disease, Imperial College London, Biomedicine, Biomarker, Siemens Healthineers, Enigma, EB, Scripps Research, CNS, Associate, Disease, CSO, Diagnosis, PET, Click chemistry, Central nervous system disease, Nobel Prize, Management
Enigma Biomedical USA (EB) today announced the appointment of Hartmuth Kolb, PhD as Chief Science Officer (CSO).
Key Points:
- Enigma Biomedical USA (EB) today announced the appointment of Hartmuth Kolb, PhD as Chief Science Officer (CSO).
- Dr. Kolb’s passion for innovation and scientific rigor has driven his extensive career and broad recognition.
- He will join Enigma at the beginning of March, 2024.
- In his 10 year tenure at Johnson & Johnson Innovative Medicine, he served as the Vice President, Neuroscience Biomarkers and Global Head of Imaging.